299 related articles for article (PubMed ID: 5364658)
1. [Effect of a combined L-Dopa and decarboxylase inhibitor (Ro 4-4602) therapy in parkinsonism patients. Quantitative analysis of bradykinesia using reaction times].
Kaufmann W; Butz P; Wiesendanger M
Dtsch Z Nervenheilkd; 1969 Dec; 197(1):85-100. PubMed ID: 5364658
[No Abstract] [Full Text] [Related]
2. [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].
Kaufmann W; Butz P; Wiesendanger M
Dtsch Z Nervenheilkd; 1970; 197(1):85-100. PubMed ID: 5522871
[No Abstract] [Full Text] [Related]
3. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
[No Abstract] [Full Text] [Related]
4. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
Gehlen W; Eisenlohr JJ
Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
[No Abstract] [Full Text] [Related]
5. [Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)].
Birkmayer W
Wien Klin Wochenschr; 1969 Sep; 81(39):677-9. PubMed ID: 5344299
[No Abstract] [Full Text] [Related]
6. [Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
Ferel D
Schweiz Med Wochenschr; 1972 Jan; 102(3):88-94. PubMed ID: 4551909
[No Abstract] [Full Text] [Related]
7. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
Birkmayer W; Linauer W; Mentasti M; Riederer P
Wien Med Wochenschr; 1974 Jun; 124(22):340-4. PubMed ID: 4275492
[No Abstract] [Full Text] [Related]
8. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
Geissbuhler F; Bartholini G; Gaillard JM; Tissot R
Encephale; 1971; 60(3):189-209. PubMed ID: 5119348
[No Abstract] [Full Text] [Related]
9. [Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor].
Guillard A
Brux Med; 1972 Oct; 52(10):673-80. PubMed ID: 4656191
[No Abstract] [Full Text] [Related]
10. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
Andrews CJ; Somerville B
Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
[No Abstract] [Full Text] [Related]
11. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
Stammler A; Vielhaber K
Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
[No Abstract] [Full Text] [Related]
12. [Dopamine and abnormal movements].
Rondot P; Dumas RJ
Rev Neurol (Paris); 1972 Jul; 127(1):99-113. PubMed ID: 4272134
[No Abstract] [Full Text] [Related]
13. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
Court J; Kase JC; Mena I; Palacios E
Rev Med Chil; 1973 Jun; 101(6):452-5. PubMed ID: 4764560
[No Abstract] [Full Text] [Related]
14. [Treatment of Parkinson's disease with L-dopa combined with a decarboxylase inhibitor].
Siegfried J; Klaiber R; Perret E; Ziegler WH
Dtsch Med Wochenschr; 1969 Dec; 94(52):2678-81. PubMed ID: 4903342
[No Abstract] [Full Text] [Related]
15. [Therapy of parkinsonism using a combination of L-dopa and decarboxylase inhibitor].
Völler GW; Muschard F
Med Welt; 1973 Apr; 24(17):705-7. PubMed ID: 4750934
[No Abstract] [Full Text] [Related]
16. Therapeutic uses and side effects of L-dopa.
Boshes B
Adv Intern Med; 1972; 18():219-49. PubMed ID: 4576081
[No Abstract] [Full Text] [Related]
17. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
Tissot R; de Ajuriaguerra J
Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
[No Abstract] [Full Text] [Related]
18. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
[No Abstract] [Full Text] [Related]
19. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
Görlich J; Markus E
Dtsch Med Wochenschr; 1972 Aug; 97(34):1246-8. PubMed ID: 5048316
[No Abstract] [Full Text] [Related]
20. [Review of current pharmacotherapy of Parkinsonism. Comprehensive review].
Benesová O
Cesk Neurol; 1973 May; 36(3):196-205. PubMed ID: 4574253
[No Abstract] [Full Text] [Related]
[Next] [New Search]
